Researchers reported at the Association for Research in Vision and Ophthalmology meeting that semi-annual optical coherence tomography-angiography imaging in eyes with intermediate non-neovascular age-related macular degeneration may be useful to stratify the risk for developing exudative choroidal neovascularization.
“OCT-A can detect the abnormal blood vessels that cause wet macular degeneration earlier than traditional imaging techniques,” according to a study summary provided to ARVO by author Bailey.
A total of 49 eyes were enrolled in the study. Forty eyes met image quality standards and had follow-up for at least 18 months. Clinical examination and 3 x 3 mm OCT angiograms were routinely obtained with fluorescein angiography, if indicated.
Conversion to CNV required at least one of the following: intra- or subretinal fluid on structural OCT, hemorrhage on examination or leakage with fluorescein angiography.
OCT-A detected nonexudative CNV in five eyes, with three of these developing exudation 1, 2 and 5 months later; one eye remined dormant for 25 months; and one eye was lost to subsequent follow-up. Four eyes developed exudative CNV despite negative OCT-A scans at the previous regular visit 2, 3, 4 and 5 months previously, researchers wrote.
In eyes without nonexudative CNV on regularly scheduled OCT-A, the risk for developing exudative CNV within the subsequent 6 months was 3.8%, according to researchers.
They suggest that OCT-A could detect nonexudative CNV in eyes with intermediate non-neovascular AMD (iAMD).
Regular semi-annual OCT-A of eyes with iAMD may be useful to determine risk for developing exudative CNV, Bailey said. Monitoring the vessels closely can help ensure appropriate and timely treatment.
Bailey ST, et al. Early detection of choroidal neovascularization with OCT angiography. Presented at: Association of Research in Vision and Ophthalmology annual meeting; May 7-11, 2017; Baltimore.
Disclosure: Bailey reports no relevant financial disclosures. Please see the abstract for all remaining authors’ financial disclosures.